One-stop clinic for assessment of risk of chromosomal defects at 12 weeks of gestation

Abstract

Prenatal diagnosis of trisomy 21 requires an invasive test in women considered to be at high risk after screening. At present, there are four screening tests. For a 5% false-positive rate, the sensitivities are approximately 30% for maternal age alone, 60–70% for maternal age and second-trimester maternal serum biochemical testing, 75% for maternal age and first-trimester fetal nuchal translucency (NT) scanning, and 90% for maternal age with fetal NT and maternal serum free β-human chorionic gonadotropin (β-hCG) and pregnancy-associated plasma protein-A (PAPP-A) at 11–14 weeks. This article examines the methodology of first-trimester screening and summarizes the results from all studies reporting on the implementation of this method.

• NUCHAL TRANSLUCENCY
• CHROMOSOMAL DEFECTS
• TRISOMY 21
• ULTRASONOGRAPHY
• SCREENING
• FREE BETA-HUMAN CHORIONIC GONADOTROPIN
• PREGNANCY-ASSOCIATED PLASMA PROTEIN-A